AMICUS THERAPEUTICS, INC.

Where It Passes

Where It Falls Short

• Valuation0% pass✗ 28▾

  All 13 investors flag FOLD's valuation

  Price / 3-yr avg EPS

  ✗Graham<= 15x

  Price-to-Book Ratio16.0x

  ✗Graham<= 1.5x

  P/E x P/B

  ✗Graham<= 22.5

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  EBIT / Enterprise Value0.7%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=0.7%, ROC=13.0%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Price / EPS

  ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)

  Price / (CFO / Shares)132.4x

  ✗Dreman< 8x

  Price / Book Value per Share16.0x

  ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)

  Valuation ReasonablenessOE Yield=-0.5%

  ✗MungerP/E < 25 or Owner Earnings Yield > 5%

  P/E or FCF YieldFCF Yield=0.7%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  P/B or P/E vs. Historical AverageP/B=16.0x

  ✗MarksP/E < 15 or P/B < 2.0

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Price / FCF per Share147.0x

  ✗Ackman<= 25

  Price vs. Trailing Low

  ✗Templeton<= 120% of trailing low (certified split-adjusted live window)

  Net income / market capitalization-0.60%; #3331/6340 (top 52.5%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Positive book equity / market capitalization+0.0610; #4948/6449 (top 76.7%)

  ✗AsnessTop 30% of eligible cross-section

  Price / Diluted EPS

  ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)

  (EPS CAGR % + Dividend Yield %) / P/E

  ✗Neff> 0.7 (Neff's published traditional edge)

  Price / Tangible Book Value per Share70.18x

  ✗SchlossP/TBV <= 1.00x (app cutoff)

  Book Value per Share Change-16.6%

  ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)

  Revenue / market capitalization+0.1411; #4106/5247 (top 78.3%)

  ✗OshaughnessyTop 10% of eligible cross-section

  (Operating cash flow - capex) / market capitalization+0.66%; #2441/4519 (top 54.0%)

  ✗OshaughnessyTop 10% of eligible cross-section

  Trailing six-month price return through the evaluation date

  ✗OshaughnessyTop 10% of eligible cross-section
• Valuation models0% pass✗ 2▾

  FOLD overvalued: all 2 models price fair value below $14.46 (median $2.66)

  Munger fair value$1.79

  ✗Munger-707.8% margin vs $14.46

  Ackman fair value$3.52

  ✗Ackman-310.8% margin vs $14.46
• Profitability6% pass✓ 6✗ 29▾

  15 of 16 flag FOLD's profitability — Graham, Buffett, Lynch +12 more

  Positive EPS (10 years)0/24 years positive

  ✗GrahamPositive EPS every year for 10 years

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Net Income Positive (10+ years)0/24 years positive

  ✗BuffettPositive every year for 10+ years

  ROE (up to 5-year arithmetic mean)-81.4%

  ✗Buffett> 15% arithmetic mean (app rule)

  Operating Margin (10-yr trend)5.2% (latest)

  ✓BuffettStable or rising over 10 years

  Free Cash Flow Proxy$-22.9M

  ✗BuffettPositive and growing

  Earnings Variance (10-yr CoV)N/A (negative mean EPS)

  ✗BuffettCoV < 0.3

  Retained Earnings Effectiveness

  ✗Buffett$1 retained -> > $1 market value created

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  ROE-9.9%

  ✗Lynch> 15%

  EBIT / Enterprise Value0.7%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=0.7%, ROC=13.0%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Net Income / Total Assets-2.85%

  ✗PiotroskiROA > 0

  ROA Change YoY-7.15% -> -2.85% (delta: +4.29%)

  ✓PiotroskiCurrent ROA > Prior ROA

  (CFO / Total Assets) vs ROACFO/Assets=3.49%, ROA=-2.85%

  ✓PiotroskiCFO/Assets > ROA

  Gross Margin Change YoY90.0% -> 88.5%

  ✗PiotroskiImproved YoY

  Pre-Tax Income / Revenue0.0%

  ✗Dreman>= 8%

  Net Income / Shareholders' Equity-9.9%

  ✗Dreman> 12%

  Margin of SafetyP/B=16.0x

  ✗PabraiP/B < 1.5 or P/E < 15

  Return on Equity-44.5% (3-yr avg)

  ✗AkreROE > 20% (3-year avg)

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Positive Net Income Frequency0/18 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  Operating Income / Revenue5.2%

  ✗Ackman>= 15%

  Net Income / Shareholders Equity-9.9%

  ✗Ackman>= 15%

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Operating Margin Trend-19.3% (2023) -> 5.2% (2025)

  ✓TempletonNon-negative operating-margin trend over 3 years

  Revenue growth vs. gross and operating margin trendgross margin 90.7% -> 88.5%, operating margin -19.3% -> 5.2%

  ✓SleepRevenue rising; gross margin flat or falling; operating margin holding

  Net income / market capitalization-0.60%; #3331/6340 (top 52.5%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Gross profit / total assets+59.09%; #478/3702 (top 12.9%)

  ✓AsnessTop 30% of eligible cross-section

  Net income / positive book equity-9.89%; #3408/5226 (top 65.2%)

  ✗AsnessTop 30% of eligible cross-section

  Negative 5-year standard deviation of ROA-0.1147; #3654/5884 (top 62.1%)

  ✗AsnessTop 30% of eligible cross-section

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized

  Positive Diluted-EPS Years0/10 years positive

  ✗Schloss>= 70% positive over 5-10 observed years (app rule)
• Debt & Leverage17% pass✓ 4✗ 11▾

  10 of 12 flag FOLD's debt & leverage — Buffett, Lynch, Dreman +7 more

  LT Debt vs Net Current AssetsLT Debt $392.7M vs NCA $438.3M

  ✓GrahamLT Debt <= Net Current Assets

  Debt/Equity & Interest CoverageD/E: 1.43, IC: 0.8x

  ✗BuffettD/E < 0.5 AND Interest Coverage > 5x

  Total Debt / Equity1.43

  ✗Lynch< 0.33

  Cash - Long-term Debt$-178.7M

  ✗LynchPositive preferred

  LT Debt / Total Assets Change49.69% -> 41.34%

  ✓PiotroskiDecreased YoY

  Current Assets / Current Liabilities2.84

  ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)

  Total Debt / Shareholders' Equity1.43

  ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x

  Debt Levels1.43

  ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3

  Interest Coverage & Debt/EBITDAIC=0.8x, D/EBITDA=9.8x

  ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x

  Total Debt / Shareholders Equity1.43

  ✗Ackman<= 1.0

  Negative debt-to-equity (higher means less debt)-1.4318; #3553/4210 (top 84.4%)

  ✗AsnessTop 30% of eligible cross-section
• Verdicts20% pass✓ 3✗ 12▾

  Split decision: 11 FAIL · 3 PASS · 2 NEUTRAL

  Overall verdict

  ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #1653✓PiotroskiPASS (F-Score 4)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✗TempletonFAIL (2/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
• Growth25% pass✓ 4✗ 9▾

  6 of 8 flag FOLD's growth — Graham, Lynch, Dreman +3 more

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  Inventory Growth vs Revenue GrowthInv: 92.6% vs Rev: 20.0%

  ✗LynchInventory growth < Revenue growth

  EPS Growth Direction$-0.29 (2009) -> $-0.09 (2025)

  ✗DremanPositive over recent years

  EPS CAGR

  ✗Dreman> 5% annualized

  Positive Net Income Frequency0/18 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  3yr Median Revenue Growth21.3%

  ✓Ackman>= 5%

  Positive EPS Growth Frequency5/5 years with positive EPS growth

  ✓AckmanPositive EPS growth in >= 3 of last 5 years

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Revenue growth vs. gross and operating margin trendgross margin 90.7% -> 88.5%, operating margin -19.3% -> 5.2%

  ✓SleepRevenue rising; gross margin flat or falling; operating margin holding

  5-year Revenue CAGR19.4%

  ✓SleepCAGR > 7%

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized
• Efficiency25% pass✓ 2✗ 9▾

  6 of 8 flag FOLD's efficiency — Buffett, Greenblatt, Piotroski +3 more

  Current Ratio2.84

  ✓Graham>= 2.0

  ROIC (3-5 yr avg)-18.2%

  ✗Buffett> 10%

  ROIC - WACC-28.2%

  ✗BuffettPositive (WACC = 10%)

  EBIT / (NWC + Net Fixed Assets)13.0%

  ✗Greenblatt> 25%

  Current Ratio Change YoY3.39 -> 2.84

  ✗PiotroskiIncreased YoY

  Revenue / Total Assets Change YoY0.67x -> 0.67x

  ✗PiotroskiImproved YoY

  Current Assets / Current Liabilities2.84

  ✓Dreman> 1.5

  Return on Invested Capital3.9%

  ✗Munger> 15%

  ROIC (high and growing)FY2023: ROIC=-11.1%; FY2024: ROIC=3.4%; FY2025: ROIC=3.9%

  ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each

  Reinvestment Rate x ROICN/A (non-positive net income)

  ✗AkreReinvestment Rate * ROIC > 10%

  ROIC (5-year)0/5 years above 12% (latest 3.9%)

  ✗SleepROIC > 12% in a majority of years
• Cash Flow30% pass✓ 4✗ 8▾

  7 of 10 flag FOLD's cash flow — Buffett, Dreman, Pabrai +4 more

  Free Cash Flow Proxy$-22.9M

  ✗BuffettPositive and growing

  FCF Positive and Growing$29.8M

  ✓LynchPositive and growing

  Operating Cash Flow$33.1M

  ✓PiotroskiCFO > 0

  (CFO / Total Assets) vs ROACFO/Assets=3.49%, ROA=-2.85%

  ✓PiotroskiCFO/Assets > ROA

  Price / (CFO / Shares)132.4x

  ✗Dreman< 8x

  P/E or FCF YieldFCF Yield=0.7%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  FCF Positive1/17 years FCF positive

  ✗MarksPositive FCF in majority of recent years

  (OCF - CapEx) / Market Cap0.7%

  ✗Ackman>= 4%

  Price / FCF per Share147.0x

  ✗Ackman<= 25

  Positive Operating Cash Flow frequency1/17 years positive

  ✗SleepPositive OCF in >= 70% of available years

  Operating Cash Flow - Capital Expenditures$29.8M

  ✓Neff> $0 (app proxy for a strong fundamental case)

  (Operating cash flow - capex) / market capitalization+0.66%; #2441/4519 (top 54.0%)

  ✗OshaughnessyTop 10% of eligible cross-section